Lantheus Holdings, Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., one of the nation's premier class action law firms specializing in securities fraud cases, is investigating potential claims against Lantheus Holdings, Inc. (LNTH).

If you purchased or held Lantheus Holdings, Inc. securities between February 26, 2025 and August 5, 2025, you may be eligible to join this class action lawsuit and seek compensation for your losses.

About Lantheus Holdings, Inc.

Lantheus Holdings is a pharmaceutical company that delivers diagnostic and therapeutic solutions, particularly in the fields of radiopharmaceutical oncology, precision diagnostics, and artificial intelligence-driven healthcare technologies.

The company is headquartered in Massachusetts and operates additional offices in New Jersey, Canada, and Sweden. Lantheus is known for its flagship product, Pylarify, a PET imaging agent used in prostate cancer diagnosis and management.

The Allegations

Investors have filed a securities class action lawsuit against Lantheus Holdings and several of its executives, alleging that the company made materially false and misleading statements during the class period from February 26, 2025 to August 5, 2025.

The core of the allegations centers on Lantheus’s representations about its key product, Pylarify. According to the complaint, Lantheus and its leadership overstated Pylarify’s market position, pricing power, and growth prospects.

The company allegedly failed to disclose that price increases and new competitive pressures were eroding Pylarify’s market share and revenues. Additionally, Lantheus is accused of not properly assessing or communicating the impact of emerging competitors, and of failing to warn investors about the risks these posed to revenue and financial guidance.

When the alleged truth began to emerge, investors were met with two significant stock price drops:

• May 7, 2025: After disappointing first-quarter results and a reduced outlook for Pylarify, Lantheus’s stock fell 23.2%, closing at $80.49.
• August 6, 2025: Following further disappointing results and a second downward revision to guidance, the stock plunged another 28.8%, closing at $51.87.

These events allegedly resulted in substantial losses for investors who purchased Lantheus securities during the class period.

Important Dates

• Class period: February 26, 2025 to August 5, 2025
• Lead plaintiff deadline: November 10, 2025
• Complaint filed: September 9, 2025

Your Rights and Next Steps

If you purchased or acquired Lantheus Holdings securities during the class period, you may have the right to participate in the class action lawsuit.

Here’s what you need to know:

• You do not need to be the lead plaintiff to benefit from any potential recovery. However, if you wish to serve as lead plaintiff, you must file a motion with the court no later than November 10, 2025.
• The lead plaintiff is typically the investor with the largest financial interest in the case and who is also willing to represent the class. The lead plaintiff works with lawyers to direct the litigation on behalf of all class members.
• Even if you do not take any action, you may still be included as a class member and could be eligible for compensation if the lawsuit is successful or settles.
• Lawyers are ready to help guide you through the process, answer your questions, and help determine your eligibility.

To protect your rights and maximize your potential recovery, it is important to act before the lead plaintiff deadline.

You May Be Entitled to Compensation

If you suffered losses as a result of purchasing or holding Lantheus Holdings securities between February 26, 2025 and August 5, 2025, you may be entitled to compensation. Lawyers are ready to help you understand your options and pursue a claim.

To participate in the investigation and learn more about your options, complete the form below.